Product Information
NOVOLIN 70-30 100 UNIT/ML VIAL is a brand product labeled by Novo Nordisk, priced at $4.6266 per ML under NDC 00169183711. Its NADAC has been published 671 times since Nov 28, 2013.
Strength
100 [iU]/mL
Manufacturer
Novo NordiskNDC
00169183711
Classification
Brand
Dosage Form
INJECTION, SUSPENSION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN HUMANApproval Type
Biologic (BLA)
FDA Application
BLA019991On Market Since
6/25/1991
Pharmacological Classes
Price Statistics
The NADAC for NOVOLIN 70-30 100 UNIT/ML VIAL has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 42.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.6266 per ML |
|---|---|
| All-time high | $13.4759 (Dec 12, 2018) |
| All-time low | $4.6262 (Aug 21, 2024) |
| 52-week high | $4.6323 |
| 52-week low | $4.6266 |
| Median price | $13.2503 |
| Average price | $10.9671 |
| Largest weekly change | -65.0% (Jan 10, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Human Insulin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NOVOLIN 70-30 100 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for NOVOLIN 70-30 100 UNIT/ML VIAL, manufactured by Novo Nordisk, is $4.6266 per ML (NDC 00169183711), effective Sep 30, 2026.
How has the price of NOVOLIN 70-30 100 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for NOVOLIN 70-30 100 UNIT/ML VIAL has declined 42.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NOVOLIN 70-30 100 UNIT/ML VIAL?
Since Nov 28, 2013, the NADAC for NOVOLIN 70-30 100 UNIT/ML VIAL has ranged from a low of $4.6262 (Aug 21, 2024) to a high of $13.4759 (Dec 12, 2018), with a median of $13.2503 per ML.
Are there cheaper alternatives to NOVOLIN 70-30 100 UNIT/ML VIAL?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NOVOLIN N 100 UNIT/ML VIAL, is $4.6226 per ML — about 0% below NOVOLIN 70-30 100 UNIT/ML VIAL.
Who manufactures NOVOLIN 70-30 100 UNIT/ML VIAL?
NOVOLIN 70-30 100 UNIT/ML VIAL (NDC 00169183711) is labeled by Novo Nordisk, and CMS classifies it as a brand product.